Skip to main content

Table 7 Main characteristics of the studies of APOE included in the review

From: Association between apolipoprotein gene polymorphisms and hyperlipidemia: a meta-analysis

First author

Year

Area

Sample size

Age (y)

Source of control

Genotyping method

Cases

 

Controls

NOS

HWE

Case

Control

Case

Control

E2/E2

E2/E3

E2/E4

E3/E3

E3/E4

E4/E4

 

E2/E2

E2/E3

E2/E4

E3/E3

E3/E4

E4/E4

χ2

P

Liang JP [37]

2008

Beijing,China

210

94

58.48

NR

HB

PCR-RFLP

2

19

2

155

32

0

 

0

9

1

75

9

0

6

0.94

0.63

Wu XH [38]

2007

Xinjiang,China

100

91

48.7 ± 10.5

43.1 ± 10.8

HB

PCR-RFLP

0

9

0

69

21

1

 

0

13

2

60

14

2

6

1.79

0.41

Zhao DD [11]

2007

Beijing,China

172

80

NR

HB

PCR-RFLP

1

18

2

124

27

0

 

0

13

0

58

9

0

7

2.03

0.36

Hu HN [39]

2007

Hubei,China

165

108

60.5 ± 8.3

63.8 ± 6.2

HB

ARMS-PCR

0

26

0

109

27

3

 

0

20

0

81

7

0

7

2.2

0.33

Zeng ZW [40]

2001

Guangdong,China

163

87

56.4 ± 3.2

58.0 ± 2.4

HB

PCR-RFLP

0

22

5

104

32

0

 

0

12

2

61

12

0

6

1.82

0.4

Zeng WY [41]

1996

Beijing,China

133

122

41–60

PB

PCR

5

17

4

88

18

1

 

1

14

2

97

8

0

7

2.87

0.24

Wang R [42]

2005

Sichuan,China

206

250

52

51

HB

PCR-RFLP

0

46

2

135

22

1

 

2

28

1

182

35

2

7

1.9

0.39

Zhu CL [43]

2005

Hubei,China

113

108

62.5 ± 7.2

63.8 ± 6.2

HB

ARMS-PCR

0

16

0

74

21

2

 

0

20

0

81

7

0

7

2.2

0.33

Tian Y [44]

2005

Sichuan,China

103

146

56.9 ± 8.5

56.3 ± 9.8

PB

PCR-RFLP

2

23

1

64

12

1

 

1

15

1

102

27

0

8

2.53

0.28

Zhang YH [45]

2004

Beijing,China

160

328

47.3 ± 13.8

40.1 ± 13.5

PB

PCR-RFLP

0

13

5

114

22

6

 

0

55

8

225

38

2

7

5.59

0.06

Jiang WM [46]

2013

Jiangsu,China

102

100

48.4 ± 9.7

50.2 ± 15.1

HB

DNA sequencing

1

9

2

64

22

4

 

0

7

1

86

6

0

7

2.19

0.33

Qian J [47]

2011

Jiangsu,China

212

100

54.6 ± 11.9

50.2 ± 15.1

HB

DNA sequencing

2

21

6

127

47

9

 

0

7

1

86

6

0

7

2.19

0.33

Liu YL [48]

2006

Shanxi,China

72

95

NR

HB

ARMS-PCR

2

8

3

45

13

1

 

0

16

3

61

15

0

7

2.66

0.26

Zhan CY [49]

2007

Beijing,China

96

95

60.0 ± 8.3

NR

HB

PCR

0

9

0

75

12

0

 

0

9

1

75

9

1

7

1.75

0.42

Luo R [50]

2006

Hubei,China

164

156

58.3 ± 7.1

53.1 ± 4.7

HB

PCR-RFLP

1

27

1

101

28

6

 

1

21

3

116

13

2

6

5.04

0.08

Zhang XM [51]

2001

Sichuan,China

74

230

56.8 ± 12.4

51.3 ± 10.3

PB

PCR-RFLP

0

10

2

56

6

0

 

2

26

1

165

35

1

7

2.27

0.32

Jiang WM [52]

2013

Jiangsu,China

93

100

56.0 ± 11.85

50.2 ± 15.1

HB

DNA sequencing

1

7

2

57

22

4

 

0

7

1

86

6

0

6

2.19

0.33

Jiang WM [53]

2012

Jiangsu,China

212

100

54.6 ± 11.85

50.2 ± 15.1

HB

DNA sequencing

2

21

6

127

47

9

 

0

7

1

86

6

0

6

2.19

0.33

Long SY [54]

2004

Sichuan,China

112

73

58.2 ± 7.9

55.1 ± 9.7

PB

PCR-RFLP

1

21

4

68

17

1

 

1

8

0

48

16

0

7

3.89

0.14

Zhang XM [55]

2001

Sichuan,China

225

230

53.0 ± 15.5

51.3 ± 10.3

PB

PCR-RFLP

1

37

5

156

23

3

 

2

26

1

165

35

1

7

2.27

0.32

ALBERT [56]

2003

Amsterdam, Netherlands

450

2018

10.8

NR

HB

PCR

0

50

10

243

135

12

 

13

261

45

1128

512

59

7

2.83

0.24

Turky H.A [57]

2018

Riyadh, Saudi Arabia

104

100

57.8 ± 9.9

44.0 ± 6.3

HB

TaqMan

1

7

2

74

18

2

 

0

4

0

85

11

0

8

0.66

0.72

Corella [58]

2000

Valencia, Spain

330

330

38.8 ± 9.1

37.6 ± 8.4

PB

PCR

0

17

5

237

69

2

 

3

50

1

252

23

1

7

1.28

0.53

Kobori [59]

1988

Kumamoto, Japan

447

188

30–69

HB

SRID

9

49

7

323

47

12

 

0

12

1

143

30

2

7

0.39

0.82

Cenarro [60]

2016

Zaragoza, Spain

288

220

47.9 ± 11.5

44.8 ± 16.0

HB

RT-PCR

0

9

1

186

72

11

 

0

19

3

160

34

4

8

2.53

0.28

Kiran [61]

2011

New Delhi, India

219

352

42.0 ± 7.9

35.2 ± 9.6

HB

PCR-RFLP

0

8

4

143

62

2

 

2

19

3

251

73

4

7

5.48

0.06

SolanasB [62]

2012

Zaragoza, Spain

312

264

48.4 ± 9.7

43.5 ± 16.9

HB

PCR

11

25

5

189

65

8

 

1

27

4

183

45

4

8

0.46

0.79

N.Ferreira [63]

2010

Minas Gerais, Brasil

109

107

48.4 ± 6.8

46.7 ± 6.6

HB

PCR-RFLP

0

10

0

77

18

4

 

0

9

0

72

25

1

7

2.26

0.32

FUMERON [64]

1988

Paris, France

59

113

NR

HB

PCR

0

5

1

35

14

4

 

1

13

1

79

16

3

6

3.96

0.14

T Kuusi [65]

1988

Helsinki, Finland

21

21

45.2 ± 0.8

46.7 ± 1.5

HB

PCR

0

1

3

2

8

7

 

0

1

0

11

8

1

6

0.44

0.8

  1. SNP single nucleotide polymorphism, PB population-based, HB hospital-based, HWE Hardy-Weinberg equilibrium, NR not reported, SRID single radial immunodiffusion